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In this issue, the British Journal of Cancer publishes an interesting
and well-conducted meta-analysis of published randomised trials
of the use of clodronate in breast cancer. Outcomes in the meta-
analysis include overall survival, metastasis free-survival and bone
metastasis-free survival. The meta-analysis is conducted indepen-
dently for patients with advanced breast cancer and in the adjuvant
setting.
In spite of several well-known positive studies in this area,
particularly a large trial by Powles et al (2002, 2006) in the
adjuvant setting, the current meta-analysis does not show
significant benefit for the use of clodronate for any of the end
points mentioned above.
In the early breast cancer setting, this seems particularly related,
as shown clearly in the forest plots in Figures 1–3 of this meta-
analysis, to heterogeneity among the trials. Although the largest
study (Powles et al, 2002, 2006) shows significant improvement in
overall survival and bone metastasis-free survival, as does the
smaller trial by Diel et al (1998) the Saarto Trial (Saarto et al,
2001, 2004) remains an outlier, showing a significant negative
effect on both overall survival and non-skeletal metastasis-free
survival, and a trend towards a negative effect on bone metastasis-
free survival. The Saarto Trial is in fact very different in outcome
from any of the other studies in either the adjuvant setting or in
metastatic disease, all of which either trend towards a positive
effect or show a significant positive effect for the use of clodronate.
Although the authors use correct statistical techniques (random
effects model) for the meta-analysis, the ‘opposite’ outcomes of the
Saarto study are problematic in interpreting a meta-analysis of this
group of trials. These difficulties are compounded by the fact that
most of the trials included in the meta-analysis are small. There are
only slightly more than 500 patients in all of the trials in advanced
breast cancer, and slightly more than 1650 in the trials conducted
in the adjuvant setting. This leaves the meta-analysis relatively
underpowered to demonstrate a significant effect on the outcomes
being studied.
Another methodologic problem of this, as of other meta-
analyses based on published data, is that there is limited ability to
examine effects over time. Powles et al (2002, 2006) have clearly
outlined in their publications that 2 years of clodronate resulted in
an early effect, which tended to wane over time after it was
discontinued. They have interpreted this to suggest that if
clodronate had been given longer, the effects might have been
more sustained, and this may well be the case. The use of hazard
ratios (HR) based on 5 year overall survival, bone metastasis-free
survival and non-skeletal metastasis-free survival does not provide
the ability to examine trends over time, and may tend to minimize
effects which may occur early because they directly relate to the
ongoing utilization of the bisphosphonate. The authors accessed
Kaplan–Meier curves or survival tables wherever possible, which
allowed some additional information, particularly for overall
survival. However, they were also reduced to using 5-year survival
estimates for some trials. This not only minimized the ability of the
authors to examine trends over time, but also reduced their access
to accurate 5-year survival rates, which adds a further methodo-
logic problem.
Within these methodologic limitations, however, it seems that
there may be more evidence tending to support a benefit for
overall survival and for bone metastasis-free survival than for non-
skeletal metastasis-free survival. For non-skeletal metastasis-free
survival, the HR of 0.89 (confidence intervals (CI)¼0.40–1.98) for
adjuvant therapy is not as ‘encouraging’ as either that for bone
metastasis-free survival which is 0.77 for advanced breast cancer
and 0.68 (CI¼0.38–1.23) for adjuvant therapy, or for overall
survival which is 0.73 (CI¼0.46–1.14) in advanced breast cancer
and 0.75 (CI¼0.31–1.82) for adjuvant therapy.
Within the methodologic limitations described, the authors
provide an excellent meta-analysis and summary of the published
material available on this subject. This analysis and review is
helpful in assessing the current state of the art of clodronate
therapy in the adjuvant or metastatic setting. It is clear from other
studies (Hortobagyi et al, 1996, 1998; Lipton et al, 1997) that
bisphosphonates used in the metastatic setting prevent or delay
skeletal-related events, reduce pain and improve quality of life.
However, it is less clear that clodronate or any bisphosphonate
reduces the development of subsequent bone metastases in bone
metastasis-free patients with other metastatic disease, or in the
adjuvant setting, nor that clodronate reduces bone metastases or
metastases in general or improves overall survival. Thus, results
from the already completed NSABP B-34 trial will be crucial in
determining the standard of care in the adjuvant setting. While the
data of Hortobyagi and Lipton is probably sufficient to suggest the
use of bisphosphonates (Hortobagyi et al, 1996, 1998; Lipton et al,
1997) in patients who have already developed bone metastases, the
current meta-analysis would suggest that there is yet insufficient
data to use bisphosphonates either in the setting of metastatic
disease which does not involve bone or in adjuvant therapy. While
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do not provide clear results, the results from the large B-34 study
in which 3000 patients were randomized to clodronate vs placebo
given for 3 years should prove definitive. This trial was activated in
December 2000 and completed accrual in 2004, but sufficient
events have not as yet occurred to provide adequate powering for
release of results and are not expected to occur until mid-2008 (E
Mamounas, personal communication, February 2007).
It is particularly important that we wait for definitive results
from the large trials or from individual patient meta-analysis
before adopting the routine use of bisphosphonates in the adjuvant
or the metastatic setting without bone involvement. Currently, we
are just beginning to understand the magnitude of a relatively
newly reported complication of bisphosphonates, that of jaw
osteonecrosis. While this has been reported much more commonly in
relation to long-term administration of intravenous bisphosphonates
(Conte et al, 1996; Bamias et al, 2005; Conte and Guarneri, 2005;
Bilezikian, 2006; Wendler and Shalowitz, 2006; Woo et al, 2006)
occasional reports have occurred with oral drugs such as clodronate
(Mavrokokki et al, 2007), alendronate (Fosamax) (Ruggiero et al,
2004; American Dental Association, 2006; Mavrokokki et al, 2007)
and risedronate (Actonel) (Ruggiero et al, 2004; Mavrokokki et al,
2007). It will be important to have results from a large randomized
trial such as B-34, which will tell us not only the efficacy of clodronate
in the adjuvant setting but also the relative risk of side effects in
comparison to a placebo control arm.
In the meantime, the use of bisphosphonates in the adjuvant
setting remains appropriate only when given as suggested in
guidelines (Brown and Josse, 2002; Hillner et al, 2003) for
osteoporosis, or in the setting of clinical trials. Their use to reduce
skeletal or non-skeletal-related metastases or to improve overall
survival is not supported by currently available data.
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